Bharat Biotech forays into CRDMO space with new cell & gene therapies arm Nucelion Therapeutics
Bharat Biotech forays into CRDMO space with new cell & gene therapies arm Nucelion Therapeutics
Bharat Biotech is venturing into advanced therapies by launching Nucelion Therapeutics, a subsidiary focused on cell and gene therapies. This new entity will offer comprehensive development and manufacturing services for innovative treatments targeting cancers, autoimmune disorders, and rare genetic diseases. Nucelion aims to provide scalable solutions, supporting global life science innovators from its state-of-the-art facility in Genome Valley.
Bharat Biotech is venturing into advanced therapies by launching Nucelion Therapeutics, a subsidiary focused on cell and gene therapies. This new entity will offer comprehensive development and manufacturing services for innovative treatments targeting cancers, autoimmune disorders, and rare genetic diseases. Nucelion aims to provide scalable solutions, supporting global life science innovators from its state-of-the-art facility in Genome Valley.
Bharat Biotech is venturing into advanced therapies by launching Nucelion Therapeutics, a subsidiary focused on cell and gene therapies. This new entity will offer comprehensive development and manufacturing services for innovative treatments targeting cancers, autoimmune disorders, and rare genetic diseases. Nucelion aims to provide scalable solutions, supporting global life science innovators from its state-of-the-art facility in Genome Valley. 
